NA
AVDL

NewEdge Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

NewEdge Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-121
Closed -$1.85K – 4222
2025
Q3 		$1.85K Hold
121
– – ﹤0.01% 3789
2025
Q2 		$1.07K Buy
+121
New +$1.06K ﹤0.01% 3711
2024
Q1 		– Sell
-1,300
Closed -$18.4K – 3830
2023
Q4 		$18.4K Hold
1,300
– – ﹤0.01% 2598
2023
Q3 		$13.4K Buy
+1,300
New +$17.4K ﹤0.01% 2489

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's AVDL Position: Q4 2025 in Review

NewEdge Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 121 shares — an estimated $1.85K sold.

NewEdge Advisors first reported a position in AVDL in Q3 2023 and held it in 4 quarters. The position peaked at $18.4K in Q4 2023. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • NewEdge Advisors reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 121 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.85K.
  • NewEdge Advisors first reported a position in Avadel Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • NewEdge Advisors's Avadel Pharmaceuticals position peaked at $18.4K in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.